Physician profile
Benedict Maniscalco
NPI 1679560486
$2,321.95
in general payments reported to CMS, 2019-2025
22 companies · $21.96 in 2025
The $21.96 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $536 · 2021: $833 · 2022: $43.99 · 2025: $21.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $392.79 | 2019-2021 | |
| Abbott Laboratories | $330.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.67 | 2019-2021 | |
| Amgen INC. | $179.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $153.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $131.25 | 2021 | |
| Biotronik INC. | $128.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $126.78 | 2019-2021 | |
| Boston Scientific Corporation | $115.20 | 2020-2025 | Accolade Sr |
| Actelion Pharmaceuticals US, INC. | $95.72 | 2019-2021 | |
| Astellas Pharma US INC | $70.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $55.46 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $52.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $51.74 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.13 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $43.49 | 2021 | |
| Preventice Services, LLC | $39.96 | 2020-2021 | |
| Cvrx, INC. | $25.34 | 2022 | |
| Amarin Pharma, INC. | $23.16 | 2019 | |
| Medtronic Vascular, INC. | $17.68 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $16.45 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Maniscalco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.